title: Adjuvant trastuzumab use in high-risk breast cancer patients may prevent development of contralateral estrogen receptor-negative breast tumors.
authors.forename: Kadri
authors.initials: K
authors.lastname: Altundag
authors.forename: Ozden
authors.initials: O
authors.lastname: Altundag
authors.forename: Rabiul
authors.initials: R
authors.lastname: Islam
authors.forename: Ozlem
authors.initials: O
authors.lastname: Gundeslioglu
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D002986:Clinical Trials as Topic; D011379:Prognosis; D011960:Receptors, Estrogen / Q000378:metabolism; D018570:Risk Assessment; D012307:Risk Factors; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D011960:Receptors, Estrogen; D000068878:Trastuzumab